The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•17 April 2026•

1 min read

Cipher Pharmaceuticals Launches Direct-to-Patient Platform for Natroba Treatment

Stylized metallic devices with 'Lilly' and 'SCYNEXIS PHARMACEUTICALS' logos, surrounded by scientific equipment, molecular structures, and data charts on a golden background.

Key Facts

1CaryHealth launched a custom digital platform to streamline patient access and delivery for Cipher Pharmaceuticals' Natroba (spinosad).

2The program aims to eliminate common obstacles in accessing treatments for head lice and scabies.

CaryHealth has officially launched a custom digital platform designed to streamline patient access and delivery for Cipher Pharmaceuticals' Natroba (spinosad). The program is specifically engineered to eliminate common obstacles encountered when accessing treatments for head lice and scabies. By utilizing a direct-to-patient (DTP) model, the partnership aims to remove logistical barriers and ensure seamless delivery of specialty prescription medications. This strategic move is expected to enhance Cipher's distribution network and potentially increase sales volume through improved market penetration. The digital transformation of the prescription process represents a significant step in modernizing pharmaceutical retail. Investors are viewing this as a positive development for Cipher's operational efficiency and long-term growth prospects.